New Zealand markets closed
  • NZX 50

    10,959.45
    -106.26 (-0.96%)
     
  • NZD/USD

    0.5630
    +0.0032 (+0.57%)
     
  • ALL ORDS

    6,664.60
    -14.10 (-0.21%)
     
  • OIL

    81.53
    +2.04 (+2.57%)
     
  • GOLD

    1,670.90
    -1.10 (-0.07%)
     

Despite shrinking by US$315m in the past week, Tandem Diabetes Care (NASDAQ:TNDM) shareholders are still up 993% over 5 years

·3-min read

It hasn't been the best quarter for Tandem Diabetes Care, Inc. (NASDAQ:TNDM) shareholders, since the share price has fallen 11% in that time. But over five years returns have been remarkably great. In that time, the share price has soared some 993% higher! So we don't think the recent decline in the share price means its story is a sad one. Of course what matters most is whether the business can improve itself sustainably, thus justifying a higher price. Unfortunately not all shareholders will have held it for the long term, so spare a thought for those caught in the 44% decline over the last twelve months. It really delights us to see such great share price performance for investors.

Since the long term performance has been good but there's been a recent pullback of 7.9%, let's check if the fundamentals match the share price.

Check out our latest analysis for Tandem Diabetes Care

Given that Tandem Diabetes Care didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last 5 years Tandem Diabetes Care saw its revenue grow at 39% per year. Even measured against other revenue-focussed companies, that's a good result. Fortunately, the market has not missed this, and has pushed the share price up by 61% per year in that time. Despite the strong run, top performers like Tandem Diabetes Care have been known to go on winning for decades. So we'd recommend you take a closer look at this one, but keep in mind the market seems optimistic.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. You can see what analysts are predicting for Tandem Diabetes Care in this interactive graph of future profit estimates.

A Different Perspective

We regret to report that Tandem Diabetes Care shareholders are down 44% for the year. Unfortunately, that's worse than the broader market decline of 12%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 61% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. If you want to research this stock further, the data on insider buying is an obvious place to start. You can click here to see who has been buying shares - and the price they paid.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here